Selinexor Sensitizes TRAIL-R2-Positive TNBC Cells to the Activity of TRAIL-R2xCD3 Bispecific Antibody

Selinexor Sensitizes TRAIL-R2-Positive TNBC Cells to the Activity of TRAIL-R2xCD3 Bispecific Antibody

Triple-negative breast cancer (TNBC) is an aggressive disease with poor prognosis and limited therapeutic options. Recent advances in the immunotherapy field have enabled the development of new treatment strategies, among which the use of bispecific antibodies (BsAbs), able to redirect T cells again...

Full description

Bibliographic Details
Main Authors: Silvia Martini, Mariangela Figini, Aurora Croce, Barbara Frigerio, Marzia Pennati, Alessandro Massimo Gianni, Cinzia De Marco, Maria Grazia Daidone, Christian Argueta, Yosef Landesman, Nadia Zaffaroni, Alessandro Satta
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:Cells
Subjects:
TRAIL-R2
bispecific antibody
selinexor
survivin
T cells
Online Access:https://www.mdpi.com/2073-4409/9/10/2231

Internet

https://www.mdpi.com/2073-4409/9/10/2231

Similar Items